Hub Group, Inc. (NASDAQ: HUBG) Under Investigation by Highful Law PLLC
Law Firm Investigates Whether Company and Its Executives Violated Federal Securities Laws Following Announced Accounting Restatement AUSTIN, Texas–(BUSINESS... Read more.
Conduent to Report Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 12, 2026
FLORHAM PARK, N.J.–(BUSINESS WIRE)–Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, plans to... Read more.
SentinelOne Delivers End-to-End AI Security from Data to Runtime
New Data Security Capabilities Advance Unified Platform Approach to Securing the Full AI Lifecycle MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–SentinelOne®... Read more.
Luminar Technologies, Inc. Announces Asset Sale Offer to Purchase Outstanding Floating Rate Senior Secured Notes due 2028
ORLANDO, Fla.–(BUSINESS WIRE)–Luminar Technologies, Inc. (OTC: LAZRQ) (the “Company” or “Luminar”), today announced that it is commencing a tender... Read more.
Nodal Exchange Achieves Strong Performance in Power and Environmental Markets in January 2026
WASHINGTON–(BUSINESS WIRE)–Nodal Exchange today announced strong performance in power and environmental markets in January of 2026. Nodal continues to... Read more.
TravelX Achieves High-Growth 2025, Driving Airline Adoption of AI-Powered Post-Booking Revenue Technology
MIAMI–(BUSINESS WIRE)–#SingaporeAirshow–TravelX, a pioneer in airline inventory and post-booking revenue management technology, provided a recap... Read more.
AM Best Upgrades Credit Ratings of First Net Insurance Company
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has upgraded the Financial Strength Rating to A- (Excellent) from B++ (Good) and the Long-Term Issuer Credit Rating... Read more.
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
LOS ANGELES–(BUSINESS WIRE)–$NAGE #Biotech—Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide)... Read more.
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
– Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified –... Read more.
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ TORONTO–(BUSINESS WIRE)–Satellos... Read more.